Search results for "MEL"

showing 10 items of 6009 documents

CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL

2019

Thromboembolic and bleeding events pose a severe risk for patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Many factors can contribute to promoting the thrombotic event due to the interaction between platelets, leukocytes, and endothelium alterations. Moreover, a significant role can be played by cardiovascular risk factors (CV.R) such as cigarette smoking habits, hypertension, diabetes, obesity and dyslipidemia. In this study, we evaluated the impact that CV.R plays on thrombotic risk and survival in patients with PV and ET .

medicine.medical_specialtyEndotheliumGastroenterologySettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicinePolycythemia veraInternal medicineDiabetes mellitushemic and lymphatic diseasesmedicinePlateletEssential ThrombocythemiaPolycythemia VeraThrombotic riskEssential thrombocythemiabusiness.industrylcsh:RC633-647.5Hematologylcsh:Diseases of the blood and blood-forming organsmedicine.diseaseObesityPolycythemia vera Essential ThrombocytemiaInfectious Diseasesmedicine.anatomical_structure030220 oncology & carcinogenesisOriginal ArticlebusinessDyslipidemia030215 immunologyMediterranean Journal of Hematology and Infectious Diseases
researchProduct

Endothelial dysfunction in morbid obesity.

2013

Morbid obesity is a chronic multifunctional disease characterized by an accumulation of fat. Epidemiological studies have shown that obesity is associated with cardiovascular and metabolic disorders. Endothelial dysfunction, as defined by an imbalance between relaxing and contractile endothelial factors, plays a central role in the pathogenesis of these cardiometabolic diseases. Diminished bioavailability of nitric oxide (NO) contributes to endothelial dysfunction and impairs endothelium- dependent vasodilatation. But this is not the only mechanism that drives to endothelial dysfunction. Obesity has been associated with a chronic inflammatory process, atherosclerosis, and oxidative stress. …

medicine.medical_specialtyEndotheliumInflammationVasodilationDiseaseNitric OxideCoronary artery diseaseInternal medicineDiabetes mellitusDrug DiscoveryNonalcoholic fatty liver diseaseWeight LossMedicineAnimalsHumansEndothelial dysfunctionPharmacologyInflammationbusiness.industrymedicine.diseaseAtherosclerosisObesity MorbidVasodilationOxidative Stressmedicine.anatomical_structureEndocrinologyCardiovascular DiseasesEndothelium Vascularmedicine.symptombusinessCurrent pharmaceutical design
researchProduct

Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction

2008

Endothelial dysfunction (ED) in the setting of cardiovascular risk factors such as hypercholesterolemia, hypertension, diabetes mellitus, chronic smoking as well as in patients with heart failure has been shown to be at least in part dependent on the production of reactive oxygen species (ROS) such as superoxide and the subsequent decrease in vascular bioavailability of nitric oxide (NO). Methods to quantify endothelial dysfunction include forearm plethysmography, flow-dependent dilation of the brachial artery, finger-pulse plethysmography, pulse curve analysis, and quantitative coronary angiography after intracoronary administration of the endothelium-dependent vasodilator acetylcholine. S…

medicine.medical_specialtyEndotheliumPathogenesisRisk FactorsDiabetes mellitusInternal medicinemedicineAnimalsHumansEndothelial dysfunctionClinical Trials as Topicbusiness.industrynutritional and metabolic diseasesGeneral MedicinePrognosismedicine.diseaseAscorbic acidPathophysiologyPrimary PreventionEndothelial stem cellOxidative StressEndocrinologymedicine.anatomical_structureCardiovascular DiseasesHeart failureCardiologyEndothelium VascularReactive Oxygen SpeciesbusinessBiomarkersAnnals of Medicine
researchProduct

Mechanisms of hypertension in the cardiometabolic syndrome

2009

Arterial hypertension is often part of a constellation of anthropometric and metabolic abnormalities that occur simultaneously to a higher degree than would be expected by chance alone, supporting the existence of a discrete disorder, the so-called metabolic syndrome. It is the result of interactions among a large number of interconnected mechanisms, which eventually lead to both an increase in cardiovascular and renal risk, and the development of diabetes. Mechanisms involved in the metabolic syndrome are obesity, insulin resistance, and a constellation of independent factors, which include molecules of hepatic, vascular, and immunologic origin with pro-inflammatory properties. At each of …

medicine.medical_specialtyEndotheliumPhysiologymedicine.medical_treatmentAdipose tissueRenin-Angiotensin SystemInsulin resistanceInternal medicineDiabetes mellitusInternal MedicinemedicineHumansObesityEndothelial dysfunctionAbdominal obesityMetabolic Syndromebusiness.industryInsulinSyndromemedicine.diseasemedicine.anatomical_structureEndocrinologyCardiovascular DiseasesHypertensionBlood VesselsEndothelium VascularMED/09 - MEDICINA INTERNAInsulin ResistanceMetabolic syndromemedicine.symptomCardiology and Cardiovascular MedicinebusinessJournal of Hypertension
researchProduct

Deleterious effect of glycation on the ability of HDL to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation

2013

Background Contrary to high-density lipoprotein (HDL) from normolipidaemic and normoglycaemic subjects, HDL from diabetic patients loses its ability to reverse the inhibition of vasorelaxation induced by oxidized low-density lipoprotein (LDL). The aim of this study was to analyze the role of glycation, a major abnormality observed in diabetes, on the impairment of the vasorelaxant effect of HDL. Methods HDL from healthy subjects was glycated in vitro by incubation in glucose 200 mmol/L for 3 days. Vasoreactivity was evaluated by the relaxation response to acetylcholine of rabbit aorta rings pre-contracted with noradrenaline, before and after 2 h incubation with or without different lipoprot…

medicine.medical_specialtyEndotheliumbusiness.industryEndocrinology Diabetes and MetabolismVasodilationmedicine.diseasechemistry.chemical_compoundEndocrinologymedicine.anatomical_structureEndocrinologyFructosaminechemistryGlycationInternal medicineDiabetes mellitusInternal Medicinemedicinelipids (amino acids peptides and proteins)businessIncubationAcetylcholinemedicine.drugLipoproteinDiabetes/Metabolism Research and Reviews
researchProduct

Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function

2012

Diabet. Med. 29, 1115–1118 (2012) Abstract Aims  The aim of this study was to investigate the vascular effects of liraglutide in patients well controlled on metformin monotherapy. Methods  Forty-four patients with Type 2 diabetes were included in the study. Main inclusion criteria were: pretreatment with metformin on a stable dosage, HbA1c < 53 mmol/mol (7.0%), age 30–65 years. Patients were randomized to receive additional liraglutide or to remain on metformin monotherapy. After 6 weeks (1.2 mg) and after 12 weeks (1.8 mg), venous blood was taken for the measurement of several laboratory markers characterizing vascular and endothelial function. In addition, retinal microvascular endothelia…

medicine.medical_specialtyEndotheliumbusiness.industryLiraglutideEndocrinology Diabetes and MetabolismUrologyType 2 diabetesVenous bloodmedicine.diseaseGlucagon-like peptide-1MetforminEndocrinologyEndocrinologymedicine.anatomical_structureDiabetes mellitusInternal medicineInternal MedicineArterial stiffnessmedicinebusinessmedicine.drugDiabetic Medicine
researchProduct

Cardiometabolic non-response to aerobic exercise: Identifying subclinical ischaemic coronary disease

2019

Sin financiación 5.864 JCR (2019) Q1, 18/138 Cardiac & Cardiovascular Systems 1.459 SJR (2019) Q1, 58/362 Cardiology and Cardiovascular Medicine; Q2, 36/104 Epidemiology No data IDR 2019 UEM

medicine.medical_specialtyEpidemiologyEnfermedad cardiovascularCardiologyMEDLINECardiometabolic responseCoronary Artery DiseaseCoronary diseaseCoronary artery diseaseInternal medicineDiabetes mellitusmedicineHumansAerobic exerciseExerciseCardiometabolic response aerobic exercise coronary disease.Subclinical infectionMetabolismobusiness.industrymedicine.diseaseaerobic exerciseDiabetes Mellitus Type 2coronary disease.Cardiovascular DiseasesCardiologyCardiopatía coronariaCardiology and Cardiovascular MedicinebusinessEuropean Journal of Preventive Cardiology
researchProduct

Epidemiological and virological studies into the poliomyelitis in Valencia (1959-1969)

2009

Studies into the polio virus began in Valencia in 1959 with the work undertaken by the microbiologist Vicente Sanchis-Bayarri Vaillant. After his education at the Rochester University and at the Pasteur Institute, Sanchis-Bayarri Vaillant established a laboratory of cell cultures at the Faculty of Medicine in Valencia, where he developed a new diagnostic technique for the poliomyelitis virus. In addition, epidemiological studies were carried out both prior to and post the 1963 vaccination campaign, which proved that Sabin’s oral vaccine was both effective and safe for use.

medicine.medical_specialtyEpidemiologyUNESCO::LINGÜÍSTICA::Lingüística aplicada::DocumentaciónPoliomielitisPoliomelitiscomplex mixtures:LINGÜÍSTICA::Lingüística aplicada::Documentación [UNESCO]History and Philosophy of ScienceCampañas de vacunaciónAZ20-999medicinePolio virusEpidemiologíaHistory of medicine. Medical expeditionsR131-687Poliomielitis; Poliovirus; Vacunas de la polio; Campañas de vacunación; Epidemiologíabusiness.industryPolio vaccinesPoliovirus Vaccinesmedicine.diseaseVaccination campaignsPoliomyelitisVaccinationPoliomyelitis virusPoliovirusVaccination CampaignsVacunas de la polioFamily medicinePolio virusHistory of scholarship and learning. The humanitiesbusinessPoliomyelitis
researchProduct

The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus.

1999

Aims/hypothesis. In recent years, evidence has arisen that proinsulin C-peptide exerts biological effects especially on microcirculation, e. g. C-peptide has been shown to increase skin microcirculation in patients with Type I (insulin-dependent) diabetes mellitus and to activate endothelial nitric oxide synthase. This study aimed to investigate the influence of proinsulin C-peptide on erythrocyte deformability which was assessed by means of laser diffractoscopy. Methods. Blood samples from healthy control subjects (n = 10) and Type I diabetic patients (n = 15) completely deficient of C-peptide were analysed at shear stresses ranging from 0.3 to 30 Pa. Results. Erythrocyte deformability was…

medicine.medical_specialtyErythrocytesEndocrinology Diabetes and MetabolismProhormoneMicrocirculationBlood cellchemistry.chemical_compoundInternal medicineDiabetes mellitusErythrocyte DeformabilityInternal MedicineMedicineErythrocyte deformabilityHumansEnzyme InhibitorsOuabainProinsulinC-Peptidebusiness.industryC-peptideLasersmedicine.diseaseRed blood cellEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 1chemistrySodium-Potassium-Exchanging ATPasebusinessmedicine.drugDiabetologia
researchProduct

Type 2 diabetes mellitus and osteoarthritis

2019

Objectives: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest. Methods: We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes. We also reviewed the literature to assess the saf…

medicine.medical_specialtyEvidence-based practicetype 2 diabetes mellituendocrine system diseasesMedicinaOsteoarthritisOverweightPathophysiologyArticle03 medical and health sciences0302 clinical medicineInsulin resistanceRheumatologyInternal medicineOsteoarthritisType 2 diabetes mellitusMedicineHumans030212 general & internal medicineObesityRisk factor030203 arthritis & rheumatologyddc:616[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systembusiness.industryType 2 Diabetes Mellitusnutritional and metabolic diseases[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseObesity3. Good healthInstitutional repositoryAnesthesiology and Pain MedicineDiabetes Mellitus Type 2[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemDisease Progressionosteoarthritimedicine.symptomInsulin ResistanceSafetybusiness
researchProduct